Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Seattle, Washington 98109


The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.

Study summary:

Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy has not been established. 77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity and clinical evidence of herpes zoster infection.


Inclusion Criteria: - 10 years or older - Both sex (male or female) - Allogeneic transplant patient for hematologic malignancy or aplastic anemia Exclusion Criteria: - Previous intolerance to acyclovir - Patients who are unavailable for follow-up - Patients in whom drug compliance may be a problem - Evidence of active VZV infection - VZV infection in the initial 1 month after transplant - Pregnant women, lactating women, or those not using adequate contraception - Creatinine > 3.0 mg/dl.



Primary Contact:

Principal Investigator
Michael Boeckh, MD
Fred Hutchinson Cancer Research Center

Backup Contact:


Location Contact:

Seattle, Washington 98109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.